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Abstract 
Mesalamine has been used as the first-line therapy for the treatment of ulcerative colitis 
(UC) because of its efficacy and fewer side effects. However, earlier study showed that 
mesalamine occasionally causes diarrhea. We are presenting a patient with active UC in 
whom bloody diarrhea accompanied by abdominal pain and fever occurred and the 
symptoms were aggravated after administration of mesalamine. In order to clarify the 
reason of symptoms aggravation, drug lymphocyte stimulation test and rechallenge trial 
with mesalamine were performed. The results indicated the possibility that aggravation 
was related to allergic reaction and was dose-dependent. Furthermore, we examined 
colonoscopic views but there was no remarkable change in before and after rechallenge 
trial. Based on the above result, the patient was diagnosed with mesalamine intolerance. 
In order to differentiate whether the exacerbation of bloody diarrhea is due to the side 
effects of the mesalamine or a true relapse of UC, taking careful history before and after 
increasing mesalamine dosage as well as being aware of side effects of mesalamine are 
required. Clinicians should be aware of diarrhea as a side effect of mesalamine 
particularly after onset of mesalamine formulation, change in mesalamine formulation, 
or change in mesalamine dose. 
Introduction 
Sulfasalazine has been the first-line therapy for mild to moderately active ulcerative 
colitis (UC) and also for maintenance of remission in UC since earlier studies [1, 2] 
demonstrated its efficacy. Sulfasalazine is a pro-drug comprising mesalamine  
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(5-aminosalicylic acid, 5-ASA) and sulfapyridine joined by an azo band. Azad Khan 
et al. [3] reported mesalamine to reduce the inflammation of UC. Azo band linkage in 
sulfasalazine enables mesalamine to reach the inflamed area of UC, where bacterial 
enzymes split the azo band [4]. There is a dose-dependent adverse event that limits acute 
and chronic use of sulfasalazine. The sulfapyridine moiety of sulfasalazine is considered 
to be attributed to most cases of mesalamine intolerance [5]. To eliminate the toxicity 
associated with sulfasalazine and to prevent mesalamine absorption in the proximal small 
bowel [6], various mesalamine formulations have been developed. Two different 
mesalamine formulations, pH-dependent release (Asacol) and time-dependent release 
(Pentasa) are now available in Japan. Since some controlled studies [7–10] demonstrated 
the efficacy and safety of mesalamine formulations, mesalamine is currently the most 
commonly used drug in the treatment of active and quiescent UC. Although mesalamine 
is recognized as a well-tolerated drug, some adverse events have also been reported. While 
allergic and nephrotoxic reactions and acute pancreatitis induced by mesalamine are well 
recognized [11, 12], diarrhea as a side effect of mesalamine treatment is rare. Here we 
present a case of mesalamine-induced exacerbation of bloody diarrhea in a patient with 
active UC. 
Case Report 
A 14-year-old male presenting with bloody diarrhea of 1 month duration was referred to our 
hospital. He was diagnosed with UC of left-sided colitis by total colonoscopy and histology. He 
started to receive pH-dependent release mesalamine (Asacol) at 3,600 mg/day, which seemed to 
aggravate bloody diarrhea and to induce abdominal pain and fever. Then Asacol was switched to 
time-dependent release mesalamine (Pentasa) at 4,000 mg/day, but the symptoms did not improve. 
Physical examination revealed high temperature (37.8°C) and mild tenderness without rebound 
tenderness in the lower quadrant abdomen.  
Laboratory examinations on admission showed that CRP was slightly elevated (1.16 mg/dl) and 
that peripheral eosinophils were normal. Cytomegalovirus antigenemia study and cytomegalovirus in 
histological results of colorectal biopsy specimen were negative. Colonoscopy on admission revealed 
disappearance of the vascular pattern and diffuse granular mucosa and erosion that was noted 
continuously from the rectum to the decending colon (fig. 1). The patient was submitted to drug 
lymphocyte stimulation test (DLST) against Asacol and Pentasa because based on his clinical course, 
we assumed that the symptoms were related to side effects of mesalamine rather than true exacerbation 
of UC. Fever, bloody diarrhea and abdominal pain completely disappeared and CRP normalized as 
soon as he discontinued mesalamine with methylpredonisolone 500 mg pulse therapy. Furthermore, 
he was started on intensive treatment of granulocyte and monocyte adsorptive apheresis (GCAP). 
DLST against Asacol and Pentasa resulted in 1,635 and 2,232%, both result being strongly positive 
(a value of more than 200% is defined as positive reaction). A rechallenge trial with mesalamine was 
performed to confirm the nature of his mesalamine intolerance objectively. After informed consent, 
he was administered 400 mg/day of Asacol the dose was increased up to 2,400 mg (fig. 2). Bloody 
diarrhea, abdominal pain and fever were noted at 1,600 mg/day, and Asacol was discontinued at 
2,400 mg/day. These symptoms disappeared only few days after of Asacol withdrawal (fig. 3). 
Regardless of apparently exacerbated clinical symptoms, there was no remarkable change in 
colonoscopic view at 2,400 mg/day compared to that prior to the rechallenge trial (fig. 4). Therefore, 
he was diagnosed to be mesalamine-intolerant and treated with predonisolone sodium phosphate 
enema (Predonema).  
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This report documents the importance of recognizing mesalamine-related side effects 
whose symptoms are similar to those of UC relapse. Mesalamine formulations have 
replaced sulfasalazine as the first-choice treatment of UC due to their less frequent 
causation of sulfa-related adverse events. However, several previous studies have reported 
mesalanine-related side effects, including severe allergic reaction. Marteau et al. [11] 
documented the incidence of Pentasa-related adverse events for 2 years (from 1 January 
1993 to 31 December 1994) in France, which was 6.6 and 9.0 per million days of therapy 
in 1993 and 1994. As far as adverse events of digestive disorders go, five cases of diarrhea 
attributed to 5-ASA were reported, which was estimated to be 0.36 per million days of 
therapy with Pentasa. In previous studies [9, 10], diarrhea as a treatment-related adverse 
event is recorded in 1.0–4.6% of patients, whereas abdominal pain and fever are recorded 
in about 1–5 and 1.5% of patients, respectively. While allergic and nephrotoxic side effects 
of mesalamine are well recognized, diarrhea as a side effect of mesalamine as well as 
mesalamine-induced abdominal pain and fever is less recognized among most clinicians. 
Interestingly, the results of DLST and the rechallenge trial in our case indicated that 
not only diarrhea as a side effect of mesalamine, but also allergic reactions were 
dose-dependent. DLST is utilized to confirm the sensitivity to a specific drug. However, 
DLST merely serves as an adjunct in the diagnosis of drug-induced allergic reaction 
because sensitivity and specificity of DLST against mesalamine are not clear. However, 
the strongly positive result of DLST in our case made us assume that the symptoms were 
associated with allergic reaction. Yet a few previous studies reported that the mechanism 
of mesalamine-induced diarrhea was dose-dependent. Scheurlen et al. [13] mentioned 
that the mechanism of diarrhea caused by mesalamine formulations was thought to be a 
concentration-dependent inhibition of ileal and colonic Na
+K
+ATPase which leads to 
reduce absorption and increased secretion of water, thus increasing the fluid load to the 
colon. Goldstein et al. [14] also reported five cases of inflammatory bowel disease 
including two cases of UC, two of Crohn disease and one of indeterminate colitis, with 
diarrhea as a side effect of mesalamine treatment. They assumed that diarrhea induced by 
mesalamine was not allergic but dose-dependent by the fact that diarrhea was easily 
controlled by reducing the dose of mesalamine in two of five cases. Furthermore, this type 
of diarrhea is usually watery and blood-tinged rather than grossly bloody. Indeed, in our 
case, watery and blood-tinged diarrhea gradually developed as the dose of mesalamine in 
the rechallenge trial increased. This result raises the possibility of a dose-dependent 
mechanism and tolerance to a moderate dose of mesalamine as induction and 
maintenance therapy.  
Rechallenge trial is the most accurate method to verify the relationship between a 
specific drug and a side effect. Marteau et al. [11] reported rechallenge trials with Pentasa 
or other 5-ASA-containing drugs (olsalazine or sulfasalazine) after adverse events in 
14 patients including one case of diarrhea, and all rechallenge trials were positive. 
Mesalamine is a key drug for treatment of UC, therefore it is sometimes necessary to 
consider a rechallenge trial for diagnosis of mesalamine intolerance. Since a rechallenge 
trial can provoke life-threatening reactions, providing informed consent is absolutely 
required. 
In terms of the influence of a rechallenge trial with mesalamine on endoscopic 
changes, Kapur et al. [15] assessed the sigmoidoscopic changes after rechallenge trial with  
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mesalamine in clinically and endoscopically quiescent UC. Sigmoidoscopy after the 
rechallenge trial showed markedly inflamed mucosa up to the descending colon as well as 
exacerbation of clinical symptoms. However, no remarkable change was observed in 
sigmoidoscopic inflammation of our case before and after the rechallenge trial, which did 
not corresponded with previous reports. Further studies are required to show whether 
mesalamine-induced diarrhea influences endoscopic findings. 
In conclusion, clinicians should be aware of diarrhea as a side effect of mesalamine, 
particularly after onset of mesalamine formulation, change in mesalamine formulation, or 
change in mesalamine dose. Further clinical and experimental studies are required to 
clarify the mechanism of diarrhea as a side effect of mesalamine formulations and to 







Fig. 1. Colonoscopy on admission revealed disappearance of the vascular pattern and diffuse granular 
mucosa that was continuously noted from the rectum to the descending colon. a Rectum. b Sigmoid 
colon. c Decending colon. d Transverse colon. e Ascending colon. f Cecum. 
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Fig. 2. Rechallenge trial with Asacol. A dose of 400 mg/day of Asacol was administered and 
increased up to 2,400 mg/day. Bloody diarrhea, abdominal pain and fever were observed at a dose 






Fig. 3. Clinical course in our case. Stool frequency, rectal bleeding and fever were reduced with 
withdrawal of mesalamine. 
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Fig. 4. Colonoscopic findings on day 19 and day 25. Colonoscopy on day 25 revealed no remarkable 
change compared to prior to administration (on day 19) of Asacol. a, d Rectum. b, e Sigmoid colon. 
c, f Descending colon. a–c Colonoscopic findings on day 19. c–f Colonoscopic findings on day 25. 
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